Ranibizumab for Myopic Neovascularization

Summary

Ranibizumab for Myopic Neovascularization is a clinical trial^[1].

Key Facts

• Ranibizumab for Myopic Neovascularization is in the country of Brazil^[2].
• Ranibizumab for Myopic Neovascularization's instance of is recorded as clinical trial^[3].
• Ranibizumab for Myopic Neovascularization's start time is recorded as +2009-07-31T00:00:00Z^[4].
• Ranibizumab for Myopic Neovascularization's end time is recorded as +2014-10-31T00:00:00Z^[5].
• Ranibizumab for Myopic Neovascularization's sponsor is recorded as Instituto de Olhos de Goiânia^[6].
• Ranibizumab for Myopic Neovascularization's main subject is recorded as myopia^[7].
• Ranibizumab for Myopic Neovascularization's number of participants is recorded as {'unit': '1', 'amount': '+20'}^[8].
• Ranibizumab for Myopic Neovascularization's title is recorded as Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization^[9].
• Ranibizumab for Myopic Neovascularization's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+21'}^[10].
• Ranibizumab for Myopic Neovascularization's ClinicalTrials.gov ID is recorded as NCT01246089^[11].
• Ranibizumab for Myopic Neovascularization's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• Ranibizumab for Myopic Neovascularization's research intervention is recorded as ranibizumab^[13].
• Ranibizumab for Myopic Neovascularization's clinical trial phase is recorded as phase IV clinical trial^[14].
• Ranibizumab for Myopic Neovascularization's research site is recorded as Instituto de Olhos de Goiânia^[15].
• Ranibizumab for Myopic Neovascularization's study type is recorded as interventional study^[16].